BLUE News and Press, bluebird bio Inc. From 06/02/21

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

CRISPR is a pioneer in the gene editing space, licensing Nobel Prize winning technology to try to treat inherited diseases, cancers, and hematological conditions. The company's lead candidate is CTX001 being developed with Vertex - a potential blockbuster treatment for Sickle Cell Dis...

bluebird bio (NASDAQ: BLUE) stock has fallen on hard times due to seemingly never-ending issues with its gene therapy, LentiGlobin. The stem-cell-derived transfusion is in phase 1/2 clinical trials for treating sickle cell disease (SCD) and received conditional marketing appro...

bluebird bio (BLUE) announces that the Committee for Medicinal Products for Human Use ((CHMP)) of the EMA has adopted positive opinion recommending marketing authorization for Skysona (elivaldogene autotemcel, Lenti-D™), a one-time gene therapy for the treatment of early cerebral adren...

SKYSONA is the first and only gene therapy recommended for approval for patients with CALD, a progressive, neurodegenerative disease As of the data cutoff date, 90% of patients (27/30) treated with SKYSONA in the pivotal ALD-102 clinical study met the primary endpoint of major...

Data from pivotal KarMMa study to be presented at ASCO21 show 24.8-month median overall survival in triple-class exposed multiple myeloma With more than 24-month median follow-up, results represent longest follow-up to date from a global clinical trial of a CAR T cell th...

bluebird bio's new therapies have strict labels due to health concerns over severe side effects, limiting the addressable markets of these new therapies. Toxicities of bluebird's new therapies point to shortcomings of its CAR-T and Leniglobin technology, lowering the economic moat of ...

bluebird bio, Inc . (Nasdaq: BLUE) announced today that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) and its cell therapy program for relapsed or refractory multiple myeloma (R/RMM) will be presented durin...

For life sciences investors, the gene therapy market is one of the most interesting plays today. The US National Library of Medicine defines gene therapies as specialized treatments using genes for the prevention or treatment of disease. Gene therapies are designed to treat ...

bluebird bio (BLUE): Q1 GAAP EPS of -$3.07 misses by $0.08.Revenue of $12.79M (-41.5% Y/Y) beats by $1.17M.Press Release For further details see: bluebird bio EPS misses by $0.08, beats on revenue